Safety of sacubitril/valsartan among older adults. Where real world data meet clinical trials results

Heart failure is a condition that is increasing its prevalence around the world due to an increase in survival in conditions such as ischemic heart disease, and because of the increase of the prevalence of elderly individuals in our societies, as heart failure prevalence increases with age. [1,2] In spite of this demographical change most of the pivotal randomised clinical trials (RCT) on drugs for heart failure include a little proportion of patients with ages above 75  years old. Older patients are often underrepresented in RCT due to the high incidence of comorbidities that cause them to fail to meet the inclusion/exclusion criteria.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research